ADCC Assay Services

Antibody-dependent cellular cytotoxicity (ADCC) is a cell-mediated immune defense mechanism. The effector cells of the immune system can actively destroy target cells whose membrane surface antigens have been bound by specific antibodies. ADCC is part of the adaptive immune response due to its dependence on a prior antibody response. It is independent of the immune complement system, which can also destroy the target, but does not require any other cells. Typical ADCC involves the activation of effector cells, which are usually called natural killer (NK) cells that interact with immunoglobulin G (IgG) antibodies. Other cells, such as macrophages, neutrophils and eosinophils can also mediate ADCC.

Both peripheral blood mononuclear cells (PBMC) and isolated natural killer (NK) cells can be used for ADCC analysis. However, in PBMC, NK cells are the mediator of the ADCC process and the main effector cells. In drug development, the ability of NK cells to bind monoclonal antibodies to target tumor cells is considered to be important for the efficacy of therapeutic monoclonal antibodies screened in ADCC analysis.

At Creative Biolabs, we recognize the interest in using pre-screened donor NK cells and integrating them into our ADCC analysis. Our ADCC products provide a convenient and powerful method to measure the efficacy of antibodies in inducing ADCC in vitro, thereby enabling customers to evaluate and rank their monoclonal antibody candidates to kill tumor/cancer cells through NK-mediated cell lysis.

Fig.1 Antibody-dependent cell-mediated cytotoxicity (ADCC).^{1, 2}

ADCC Reporter-based Technology

Our ADCC product portfolio is based on the reporter gene system and provides a convenient and powerful method to measure the efficacy of antibodies in inducing ADCC in vitro.

This is achieved by combining cleverly engineered effector cells that closely resemble the natural FcγRIIIA signal transduction pathway with homologous target cells with controlled antigen expression (+) or depletion (-). In summary, our unique ADCC product portfolio provides unparalleled sensitivity for each target, and the system is indeed greater than the sum of its parts.

Features of our ADCC analysis service:

• Allow customers to evaluate and rank the effectiveness of their monoclonal antibody candidates in killing tumor/cancer cells
• Suitable for the development of antibody drugs
• Compatible with bispecific antibodies and other immune cell recruiters
• Use primary cells (PBMC, unscreened NK cells or pre-screened NK V158 + cells) to make more clinically meaningful decisions
• If necessary, provide flow cytometer-based readings and other intracellular analysis
• Can be customized according to your program needs

Sample Data

ADCC Product Portfolio

The ADCC product portfolio includes cell lines provided in an "assay-ready" format, which allows quick and convenient workflows and further reduces assay variability, making it useful for antibody screening, characterization, stability and performance studies.

For more detailed information about our FcγRIIIA/ CD16a binding assay services, please feel free to contact us or directly sent us an inquiry.

ADCC Cell lines More...

References

1. Tallima, Hatem, Hassan ME Azzazy, and Rashika El Ridi. "Cell surface sphingomyelin: Key role in cancer initiation, progression, and immune evasion." Lipids in Health and Disease 20.1 (2021): 150.
2. under Open Access License CC BY 4.0, without modification.